ESPR (STOCKS)
Esperion Therapeutics, Inc.
$2.223600
+0.053600 (+2.47%)
Prev close: $2.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sheldon L. Koenig
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $570.12M
- Employees
- 304
- P/E (TTM)
- -10.36
- P/B (TTM)
- -1.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $403.14M |
| Benefits Costs and Expenses | $423.98M |
| Costs And Expenses | $423.98M |
| Operating Expenses | $342.86M |
| Selling, General, and Administrative Expenses | $165.79M |
| Other Operating Expenses | $177.08M |
| Operating Income/Loss | $60.27M |
| Income/Loss From Continuing Operations After Tax | -$22.68M |
| Income/Loss From Continuing Operations Before Tax | -$20.84M |
| Income Tax Expense/Benefit | $1.84M |
| Income Tax Expense/Benefit, Current | $1.84M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$22.68M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$22.68M |
| Net Income/Loss Available To Common Stockholders, Basic | -$22.68M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.11 |
| Diluted Earnings Per Share | -$0.11 |
| Basic Average Shares | 207,865,080 |
| Diluted Average Shares | 207,865,080 |
| Assets | $465.89M |
| Current Assets | $462.57M |
| Inventory | $105.12M |
| Other Current Assets | $357.45M |
| Noncurrent Assets | $3.32M |
| Fixed Assets | $338.00K |
| Other Non-current Assets | $2.98M |
| Liabilities | $767.85M |
| Current Liabilities | $300.81M |
| Accounts Payable | $65.07M |
| Wages | $11.94M |
| Other Current Liabilities | $223.80M |
| Noncurrent Liabilities | $467.04M |
| Equity | -$301.97M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$301.97M |
| Liabilities And Equity | $465.89M |
| Net Cash Flow From Operating Activities | -$13.09M |
| Net Cash Flow From Operating Activities, Continuing | -$13.09M |
| Net Cash Flow From Investing Activities | -$23.09M |
| Net Cash Flow From Investing Activities, Continuing | -$23.09M |
| Net Cash Flow From Financing Activities | $36.18M |
| Net Cash Flow From Financing Activities, Continuing | $36.18M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$22.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$22.68M |
| Other Comprehensive Income/Loss | -$22.68M |